• News
  • Technology

Fish & Richardson first in biotech and patents

Related Special Reports

Realizing the significance that biotechnology would one day have on the United States and throughout the world, Fish & Richardson was one of the first law firms to venture into the field of biotech law. The firm's forward thinking was the foundation for what today is one of the largest biotechnology law practices in the United States and the largest biotechnical and pharmaceutical patent law practice in San Diego.

In 1988, when the area of biotechnology was just emerging, the firm obtained the first patent on an animal: the Harvard Mouse (aka Oncomouse), a laboratory mouse that had been genetically modified to be predisposed to certain cancers.

Dr. Stephanie Seidman

Just 17 years later, the firm's national biotech group has grown to more than 100 professionals, including 50 Ph.D.s, making it one of the largest biotechnology law practices in the country. The technical expertise of Fish & Richardson's biotech professionals is unmatched, covering virtually all biotechnology-related areas.

Locally, the firm has 25 professionals committed to serving biotech clients. Fish & Richardson's San Diego biotechnical and pharmaceutical patent law group is led by Dr. Stephanie Seidman. Seidman has earned a national reputation as a one of the top biotech patent lawyers by the complex patent work she provides to high profile and startup biotechnical companies.

With advanced degrees in chemistry, physics, molecular science and biochemistry, Seidman understands the science behind a client's invention like few other attorneys do. Her strength lies in managing complex biotechnical and chemical dockets, and strategic counseling with particular expertise in counseling emerging and early stage companies.

Seidman's U.S. and foreign patent practice includes biotechnology cases, as well as organic, including pharmaceutical and small molecules, and inorganic chemistry cases.

She also has first-hand insight into how the patent process works, which is a great benefit to the clients she serves. After attending law school, Seidman was an examiner with the Patent and Trademark Office.

She has authored several articles on IP issues. Last year she wrote a chapter for "Inside the Minds: The Art & Science of Patent Law." Her chapter, entitled "Taking Proper Care of a Client's Valuable Assets," covered a variety of areas including patenting strategy, the patent application process, the patent office and patent examiners, hiring in the patent law field, and challenges for patent practitioners.

She is currently writing a book on a biotech and pharmaceutical IP issues which is scheduled to be published later this year.

Fish & Richardson's San Diego biotechnical and pharmaceutical patent law group's commitment to clients is mirrored throughout the firm's eight other U.S. offices. The firm's biotech professionals are focused on helping clients to evaluate how intellectual property assets fit into their business strategy so that investments made in IP protection yield the highest possible returns.

Fish & Richardson attorneys have helped clients establish market exclusivity in core technology, generate revenue from dormant patents in noncore technologies, verify the strength and value of intellectual property to be acquired or sold, avoid or expediently resolve intellectual property disputes, and locate valuable patents for use in claims and counterclaims.

Submitted by Fish & Richardson

User Response
0 UserComments